Eosinophilic Esophagitis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Eosinophilic Esophagitis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as AstraZeneca, Amgen, Ellodi Pharmaceuticals, Bristol Myers Squibb (BMS), Revolo Biotherapeutics, EsoCap, Pfizer and more...

[Nevada, United States] - DelveInsight's "Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Eosinophilic Esophagitis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Eosinophilic Esophagitis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Eosinophilic Esophagitis Market Report:
• The Eosinophilic Esophagitis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Sanofi announced a Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE)
• In October, 2024: Celgene announces a Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects With Active Eosinophilic Esophagitis.
• In September, 2024: AstraZeneca announced a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).
• In September, 2024: NexEos Diagnostics, Inc. announced an Open-label Phase 2 Study Assessing the Safety, Tolerability and Preliminary Diagnostic Performance of a Radioactive Imaging Agent, NDX-3315 and NDX-3324, in Healthy Adult Participants and Patients with Eosinophilic Esophagitis
• As per the study by Kamat et al. (2021), the annual prevalence of EoE increased over time, from 79 per 100,000 enrollees in 2015 to 117 per 100,000 in 2018. In 2018, the overall prevalence was 68 per 100,000 for children aged under 10, ranged 115- 23 per 100,000 for children and adolescents aged 10-19, ranged 93-164 per 100,000 for adults aged 20-64, and was 57 per 100,000 for older adults aged over 65.
• As per the National Organization of Rare Disorders (2024), the frequency of EoE has been estimated to be 1 in 2,000 individuals. This condition has been reported in multiple continents, including Europe and America .
• Key Eosinophilic Esophagitis Companies are as follows: AstraZeneca, Amgen, Ellodi Pharmaceuticals, Bristol Myers Squibb (BMS), Revolo Biotherapeutics, EsoCap, Pfizer and more...
• Key Eosinophilic Esophagitis Therapies are as follow: DUPIXENT (dupilumab), Cendakimab (CC-93538/RPC4046), TEZSPIRE (Tezepelumab), APT-101, Etrasimod, Dupilumab, CC-93538, NDX-3324
• Launching multiple stage Eosinophilic Esophagitis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Eosinophilic Esophagitis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Eosinophilic Esophagitis Overview:
Eosinophilic Esophagitis (EoE) is an emerging chronic inflammatory disease of the esophagus characterized by upper gastrointestinal symptoms, including dysphagia and esophageal food impaction. The histopathological manifestations involve intraepithelial infiltration of eosinophils (=15 Eos/HPF) and remodeling of the esophageal epithelium, including Basal Zone Hyperplasia (BZH) and Dilated Intercellular Spaces (DIS), which can lead to strictures and narrow-caliber esophagus.

Eosinophilic Esophagitis Epidemiology Segmentation:
The Eosinophilic Esophagitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Eosinophilic Esophagitis Age-specific Cases
• Eosinophilic Esophagitis Total Diagnosed Prevalent Cases
• Eosinophilic Esophagitis Gender-specific Cases

For more information about Eosinophilic Esophagitis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Eosinophilic Esophagitis Market Insights
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated condition characterized by the presence of eosinophils (a type of white blood cell) in the esophagus, leading to inflammation, tissue damage, and dysfunction. This results in symptoms like difficulty swallowing (dysphagia), food impaction, chest pain, and heartburn. It is considered a rare disease but has seen a notable rise in cases over recent years. The EoE market is expanding as new therapies, particularly biologics, enter the field to provide more effective treatment options than traditional corticosteroids.

Eosinophilic Esophagitis Drugs Uptake
• Dupilumab was approved by the FDA for EoE, marking the first biologic therapy specifically indicated for the condition. It is an IL-4 receptor alpha antagonist that inhibits IL-4 and IL-13 signaling pathways, which are critical in the pathogenesis of allergic inflammation in EoE.
• Despite the emergence of biologics, topical corticosteroids remain widely used for mild-to-moderate EoE cases due to their cost-effectiveness. However, long-term use can lead to side effects such as esophageal candidiasis.
• PPIs are still commonly prescribed as a first-line therapy, especially for patients with mild symptoms or those not suitable for corticosteroid therapy. However, they are less effective in more severe cases.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Eosinophilic Esophagitis Therapies and Key Companies:
• DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
• Cendakimab (CC-93538/RPC4046): Bristol Myers Squibb (BMS)
• TEZSPIRE (Tezepelumab) : AstraZeneca/Amgen
• APT-101: Ellodi Pharmaceuticals
• Etrasimod: Pfizer
• Dupilumab: Sanofi
• CC-93538: Celgene
• NDX-3324: NexEos Diagnostics, Inc.

Eosinophilic Esophagitis Epidemiology:
EoE affects an estimated 1 in 2,000 individuals globally, with a higher prevalence in North America and Europe. Prevalence rates in the United States are around 50-100 cases per 100,000 individuals. The incidence of EoE is estimated to be 7-13 cases per 100,000 people annually, with a notable increase in both children and adults.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Eosinophilic Esophagitis Market Drivers:
• Rising Prevalence
• Improved Awareness and Diagnosis
• Unmet Medical Needs
• Pediatric Market Growth

Eosinophilic Esophagitis Market Barriers:
• High Cost of Biologics
• Limited Therapeutic Options
• Side Effects of Existing Therapies
• Complex Disease Pathophysiology

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Eosinophilic Esophagitis Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Eosinophilic Esophagitis Companies: AstraZeneca, Amgen, Ellodi Pharmaceuticals, Bristol Myers Squibb (BMS), Revolo Biotherapeutics, EsoCap, Pfizer and more...
• Key Eosinophilic Esophagitis Therapies: DUPIXENT (dupilumab), Cendakimab (CC-93538/RPC4046), TEZSPIRE (Tezepelumab), APT-101, Etrasimod, Dupilumab, CC-93538, NDX-3324
• Eosinophilic Esophagitis Therapeutic Assessment: Current marketed and emerging therapies
• Eosinophilic Esophagitis Market Dynamics: Eosinophilic Esophagitis Market drivers and Eosinophilic Esophagitis barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Eosinophilic Esophagitis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Eosinophilic Esophagitis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. EoE Market Overview at a Glance
4. Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Treatment of EoE
9. Treatment Guidelines for EoE
10. Epidemiology and Patient Population
11. Patient Journey
12. Marketed Therapies
13. Emerging Therapies
14. Market Analysis
15. KOL Views
16. SWOT Analysis
17. Unmet Needs
18. Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.